Company Analysis

Nurix Therapeutics, Inc. (NRIX)

Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Grade5.9
◀ Past 6.2● Present 5.7▶ Future 5.9
1 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in November.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingNov 30, 2025Nov 30, 2024Nov 30, 2023Nov 30, 2022Nov 30, 2021Nov 30, 2020Nov 30, 2019
Report filedJan 28, 2026Jan 28, 2025Feb 15, 2024Feb 9, 2023Jan 28, 2022Feb 16, 2021·
Revenue83,98054,54976,98738,62729,75017,82031,115
Research and development316,903221,632189,148184,497116,43466,49445,025
General and administrative52,74345,94442,90237,99731,20216,3098,326
Total operating expenses369,646267,576232,050222,494147,63682,80353,351
Operating income-285,666-213,027-155,063-183,867-117,886-64,983-22,236
Income before income taxes-263,697-193,299-143,948-180,360-117,063-63,777-21,460
Income tax expense76027000131-20,535239
Net income including non-controlling interests····-117,194-43,242-21,699
Net income-264,457-193,569-143,948-180,360-117,194-43,242-21,699
Earnings per share, basic-3.05-2.88-2.65-3.71-2.73··
Earnings per share, diluted-3.05-2.88-2.65-3.71-2.73··
Earnings per share, basic and diluted····-2.73-2.76-6.59
Weighted average shares, basic86,666,90767,120,26654,337,90148,607,99042,895,383··
Weighted average shares, diluted86,666,90767,120,26654,337,90148,607,99042,895,383··
Weighted average shares, basic and diluted····42,895,38315,673,4243,292,514
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton NRIX · research, not advice